📢 Call for Abstracts is now open for #KidneyWk

Bring research abstracts or clinical case reports to a global stage. Share discoveries, gain recognition, and be part of the work shaping the future of kidney health.

🗓️ Deadline: Wednesday, May 13, 2:00 p.m. EDT
🔗http://asn.kdny.info/eAP450YB1rU

Two days remain to apply for Cele’s Champions, supporting patients and care partners to attend #KidneyWk with travel funding and registration, plus ASN membership.

Amplify the patient voice and represent 850 million people worldwide living with kidney diseases. ➡️ http://asn.kdny.info/GfFt50YyrIg

The patient voice belongs at ASN Kidney Week. Cele’s Champions provides travel support to attend #KidneyWk, plus ASN membership.

Bring your perspective forward as an individual living with kidney disease or care partner representing 850 million people worldwide

🔗 http://asn.kdny.info/AnIy50YyPTi

#COVID-19 Vaccinations and Kidney Disease Outcomes
Presentation given at #HealthWatchUSA February 18th 2026
Summarizes the work we presented at #kidneywk 2025 based on the #TrinetX EMR database
https://www.youtube.com/watch?v=StZRHQxcD7Q

#COVID-19 Vaccinations and Kidney Disease Outcomes
Presentation given at #HealthWatchUSA February 18th 2026
Summarizes the work we presented at #kidneywk 2025 based on the #TrinetX EMR database
www.youtube.com/watch?v=StZR...

What’s inside Kidney Week On-Demand? 🌍
Step into 250+ hours from #KidneyWk 2025, featuring advanced clinical insights, cutting-edge research, three years of access, and continuing education credits for select sessions from the world’s premier nephrology meeting.
🔗 http://asn.kdny.info/rQuN50YhJjx

Health Watch USA to Examine COVID-19 Vaccination and Kidney Disease Outcomes | Infection Control Today Join Health Watch USA on February 18, 2026, as Christos Argyropoulos, MD, PhD, MS, FASN, discusses how repeated COVID-19 vaccinations compare with COVID-19 disease in patients with kidney disease,…

I will be talking later today (February 18th) about #COVID19 infection & vaccination kidney outcomes. This is work done with electronic health records (#TrinetX) by our group that was presented at the ASN #KidneyWk 2025.
Announcement and zoom link
www.infectioncontroltoday.com/view/health-...

Original post on mastodon.social

I will be talking later today (February 18th) about #COVID19 infection & vaccination kidney outcomes. This is work done with electronic health records (#TrinetX) by our group that was presented at the ASN #KidneyWk 2025.
Announcement and zoom link […]

tweets about flozin term from 2020

yup - after #KidneyWk 2020
Alicia McDonough and @juancarlosqvelez.bsky.social were calling them -gliflozins and -flozins so we went to the next step!

At #KidneyWk 2025, onconephrology innovations took center stage with many oral presentations showcasing updates, therapies, and mechanisms. Read about the field's progress in #ASNKidneyNews: kidney.pub/KN1801-12

#KidneyWk used to be a highlight of my year and I was really proud to support @asnkidney.bsky.social .
Its tacit acceptance of Donald Trump and his actions has been a major disappointment for me.
So, yes …👇

Nice @kidneyboy.bsky.social

Love the frigid run

I might be able to keep up with you, maybe run together at #KidneyWk later this year?

Conservative kidney management (CKM), is an active, patient-centered approach to managing advanced kidney failure without dialysis, has a growing base of evidence, and was featured at #KidneyWk 2025. Read more in #ASNKidneyNews: kidney.pub/KN1801-15

Far more patients with kidney disease are eligible for home-dialysis compared to those who engage in it. A recent panel at #KidneyWk 2025 says education is critical to adopting the technology: kidney.pub/KN1801-03 #ASNKidneyNews

At #KidneyWk 2025, four people with kidney disease discussed how dietary changes helped keep their conditions in check. Now, they're working on a kidney cookbook. Read more about their experiences in #ASNKidneyNews: kidney.pub/KN1801-23

At #KidneyWk 2025, Rebecca Schmidt presented multifaceted strategies to expand kidney care to rural areas. Read #ASNKidneyNews coverage of the presentation here: kidney.pub/KN1712-18

Sparsentan Safe and Effective for Pediatric Patients With FSGS | Docwire News A subanalysis of DUPLEX study data showed sparsentan resulted in proteinuria reduction for pediatric patients with focal segmental glomerulosclerosis (FSGS).

Pediatric results from DUPLEX show sparsentan is well tolerated and achieves superior, sustained proteinuria reduction versus the maximum IRB dose in FSGS. #KidneyWk #nephsky #Nephrology #FSGS #Pediatrics www.docwirenews.com/post/sparsen...

Targeting CD38+ Cells | Docwire News Georg Böhmig, MD, discussed the role of CD38+ cells in immune-mediated kidney disease and felzartamab as a treatment for antibody-mediated rejection in kidney transplantation.

What role do CD38+ immune cells play in AMR and glomerular disease? Georg Böhmig, MD, shares insights from #KidneyWk and what’s next for CD38-targeted therapies. #nephrology #nephsky #kidneytransplantation #kidneydisease www.docwirenews.com/post/targeti...

Povetacicept Shows Disease-Modifying Potential in IgAN and Primary MN | Docwire News Povetacicept showed sustained proteinuria reduction and stable glomerular filtration rate at 48 weeks for patients with IgA nephropathy and primary membranous nephropathy.

ICYMI: RUBY-3 demonstrates that targeting BAFF and APRIL with povetacicept can drive proteinuria reduction and immunologic remission in IgAN and pMN. #KidneyWk #nephsky #Nephrology #ClinicalTrials www.docwirenews.com/post/povetac...

Intensive BP Lowering Offers Benefit to Patients With CKD | Docwire News Most patients with hypertension and chronic kidney disease (CKD) benefited from intensive BP lowering, especially those with more advanced CKD, an analysis of SPRINT data showed.

SPRINT data show intensive BP control favors most CKD patients, with greatest net benefit in those with lower eGFR. #KidneyWk #nephrology #CKD #hypertension #nephsky www.docwirenews.com/post/intensi...

Proteinuria Reduction in IgAN With Sibeprenlimab Sustained at 12 Months | Docwire News An interim analysis of VISIONARY data showed that sibeprenlimab sustains reductions in proteinuria and key disease biomarkers in patients with IgA nephropathy (IgAN) at 12 months.

ICYMI: 12-month VISIONARY results show sibeprenlimab sustains proteinuria reduction and remission in IgA nephropathy. #KidneyWk #nephrology #IgAN #kidneydisease #nephsky www.docwirenews.com/post/protein...

⏳ Final hours to claim your CME, CNE, CPE credits and MOC points from #KidneyWk 2025. Submit evaluations and share feedback for this year’s Early Programs and Annual Meeting sessions by 11:59 p.m. EST.

Log in to the ASN eLearning Center now. 👉 http://asn.kdny.info/gA2650XHQue

Hypertension and Pregnancy | Docwire News Joel Topf, MD, and Vesna Garovic, MD, PhD, discussed pregnancy and hypertension, the topic of her inaugural Sharon Silbiger, MD, Endowed Lecture at ASN Kidney Week 2025.

ICYMI: Joel Topf @kidneyboy.bsky.social spoke with Vesna Garovic of Mayo Clinic at #KidneyWk about pregnancy and hypertension, the topic of Dr. Garovic's inaugural Sharon Silbiger, MD, Endowed Lecture. #nephsky #nephrology #hyptertension #pregnancy www.docwirenews.com/post/hyperte...

The world’s premier nephrology meeting is on demand. Kidney Week On-Demand™ features 250+ hours of sessions from #KidneyWk 2025, covering science, clinical care, and innovation.

Want more? Seven Early Programs are also available separately for deep-dive education.

http://asn.kdny.info/2YBI50XHPJZ

ASN Kidney Week 2025 | Docwire News Review highlights from abstracts and presentations at ASN Kidney Week 2025, presented by the American Society of Nephrology, on Nephrology Times

Don't miss our Kidney Week coverage, including research news and interviews with researchers and presenters. #nephrology #kidneywk #nephsky www.docwirenews.com/conference/a...

A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial - PubMed ClinicalTrials.gov Identifier: NCT04218370.

11/10
Up next 12/16/25 we’re talking about AKI and best strategies for renal recovery from dialysis #nephjc
LIBERATE-D, simultaneous @jama.com publication during #KidneyWk pubmed.ncbi.nlm.nih.gov/41201895/

Lorundrostat and Aldosterone Synthase Inhibition for Hypertension | Docwire News Matthew Weir discussed research from ASN Kidney Week showing lorundrostat reduced systolic BP and albuminuria and had benefits for chronic kidney disease (CKD) and hypertension.

WATCH Matthew Weir, MD, discussing results from the phase 2 Explore-CKD trial of lorundrostat presented at #KidneyWk. #nephrology #nephsky #kidneydisease #CKD #hypertension
www.docwirenews.com/post/lorundr...

One week left! Don’t miss your chance to claim continuing education credits and MOC points.

If you attended #KidneyWk, be sure to:
✅ Complete evaluations
✅ Share your feedback
✅ Claim CME, CNE, and CPE credits, and MOC points

📅Deadline: Wednesday, December 17
🔗 http://asn.kdny.info/Ni8Y50XFMxt

Therapies for IgA nephropathy and lupus took center stage in the High-Impact Trials sessions at ASN Kidney Week 2025. Read about a trio of therapies presented in #ASNKidneyNews: kidney.pub/KN1712-02 #KidneyWk

52-Week Data Show Sustained Benefits of Pegcetacoplan in C3G | Docwire News Dr. Carla Nester discussed VALIANT 52-week data presented at ASN Kidney Week 2025 showing sustained proteinuria reduction with pegcetacoplan in complement 3 glomerulopathy (C3G).

Dr. Carla Nester discussed 52-week data on pegcetacoplan for #C3G demonstrating sustained proteinuria reduction (and remission in a third of patients). #nephrology #nephsky #glomerulardisease #kidneywk www.docwirenews.com/post/52-week...